SpectraCure to participate in a large research programme funded by Knut and Alice Wallenberg Foundation

SpectraCure will be an industrial participant in a large research programme in quantum technology, WACQT – Wallenberg Center for Quantum Technology, funded mainly by Knut and Alice Wallenberg Foundation. SpectraCure will receive funding to pay the salary of a researcher at the research school for PhD students covered by the program. The researcher will be employed by SpectraCure and conduct research together with a research team at the Department of Physics at Lund University.

The research will be about a new method of measuring laser light deep into the human body without having to use optical fibres and needles, using advanced quantum sensor technology.

– This is research that will be very interesting for SpectraCure, as our treatment method is about delivering laser light to cancer tumours deep inside the body, says SpectraCure's CTO Johannes Swartling.

The financial contribution to SpectraCure are approximately 2,5 MSEK.

About WACQT

Wallenberg Centre for Quantum Technology is a large national research programme with a total budget of approximately 1 billion SEK. The aim is to strengthen Swedish research and industry in different areas in the field of quantum technology. The project is led by Chalmers University of Technology in Gothenburg, where research focusing on building quantum computers is performed. SpectraCure participates in another branch of the programme within quantum sensors, i.e., sensors that are based on quantum physics phenomena. The research within quantum sensors is coordinated by a research group at Lund University.

For more information see the programme’s website:

https://www.chalmers.se/en/centres/wacqt/

For further information, please contact:
SpectraCure AB publ, CEO, Masoud Khayyami, phone: +46 (0) 70 815 21 90

This information is information that SpectraCure AB is required to disclose under the EU Market Abuse Regulation. The information was provided, through the contact of the above contact person, for publication on January 18th, 2018.

SpectraCure in short

SpectraCure was founded in 2003 as a spin off from Lund University departments for medical laser applications and physics. The company focuses on cancer treatments using medical systems with laser light sources and reactive drugs, which is referred to as "Interstitial Photodynamic Therapy", PDT, a treatment methodology suitable for internal solid tumours of various kind, e.g. prostate and abdominal salivary glands, but also other indications such as cancer of the head and neck.

Release

SpectraCure is developing the future systems for the treatment of internal solid cancer tumours. The goal of the proprietary and patented treatment system is to eliminate deep-seated cancer tumours and prolong the survival of cancer patients while maintaining their quality of life. When prostate cancer recurs, there are often no established treatment options other than lifelong hormone therapy, with its associated side effects. 

Facebook Linkedin Envelope